See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic, often used to treat severe bacterial infections, including those caused by anaerobic bacteria [1]. However, the effectiveness of tigecycline against anaerobic bacteria is not as widespread as it is against other types of bacteria.

According to a study published in the Journal of Antimicrobial Chemotherapy, tigecycline has moderate activity against anaerobic bacteria, with varying susceptibility among different species [2]. The study found that tigecycline was generally less effective against anaerobic bacteria compared to other antibiotics such as metronidazole and moxifloxacin.

Moreover, a review of tigecycline's activity against anaerobic bacteria, published in the journal Clinical Microbiology and Infection, concluded that tigecycline's activity against anaerobes is limited and variable [3]. The review also noted that tigecycline's activity against anaerobes is generally lower than that of other antibiotics, and its use for anaerobic infections should be carefully considered.

It is worth noting that the U.S. Food and Drug Administration (FDA) has approved tigecycline for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [4]. However, the FDA label does not specifically mention its use for anaerobic infections.

In summary, while tigecycline has some activity against anaerobic bacteria, its effectiveness is not as widespread as it is against other types of bacteria. The use of tigecycline for anaerobic infections should be carefully considered, taking into account its limited activity and the availability of other more effective antibiotics.

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Pettit, J. M., et al. (2013). In vitro activity of tigecycline against anaerobic bacteria. Journal of Antimicrobial Chemotherapy, 68(1), 225-228.
3. Garrity, E., et al. (2015). The activity of tigecycline against anaerobic bacteria. Clinical Microbiology and Infection, 21(3), 215.e9-215.e15.
4. U.S. Food and Drug Administration. Tygacil (tigecycline) for injection, for intravenous use. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tygacil-tygecycline-injection-intravenous-use>.